-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

Benzinga·06/11/2026 12:46:37
Listen to the news
Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $50.